Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $3.28 billion. The enterprise value is $2.56 billion.
| Market Cap | 3.28B |
| Enterprise Value | 2.56B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 78.53 million shares outstanding. The number of shares has increased by 4.49% in one year.
| Current Share Class | 78.49M |
| Shares Outstanding | 78.53M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +16.94% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 90.56% |
| Float | 71.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20,730.80 |
| Forward PS | 1,013.57 |
| PB Ratio | 4.58 |
| P/TBV Ratio | 4.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16,220.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.82, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.82 |
| Quick Ratio | 11.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.88% and return on invested capital (ROIC) is -29.56%.
| Return on Equity (ROE) | -43.88% |
| Return on Assets (ROA) | -27.62% |
| Return on Invested Capital (ROIC) | -29.56% |
| Return on Capital Employed (ROCE) | -45.19% |
| Weighted Average Cost of Capital (WACC) | 8.84% |
| Revenue Per Employee | $798 |
| Profits Per Employee | -$1.52M |
| Employee Count | 198 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.73% in the last 52 weeks. The beta is 0.84, so CLDX's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +94.73% |
| 50-Day Moving Average | 35.04 |
| 200-Day Moving Average | 29.98 |
| Relative Strength Index (RSI) | 72.29 |
| Average Volume (20 Days) | 959,859 |
Short Selling Information
The latest short interest is 7.66 million, so 9.76% of the outstanding shares have been sold short.
| Short Interest | 7.66M |
| Short Previous Month | 7.74M |
| Short % of Shares Out | 9.76% |
| Short % of Float | 10.77% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
In the last 12 months, CLDX had revenue of $158,000 and -$300.55 million in losses. Loss per share was -$4.34.
| Revenue | 158,000 |
| Gross Profit | -244.92M |
| Operating Income | -325.83M |
| Pretax Income | -300.55M |
| Net Income | -300.55M |
| EBITDA | -322.43M |
| EBIT | -325.83M |
| Loss Per Share | -$4.34 |
Balance Sheet
The company has $717.59 million in cash and $4.90 million in debt, with a net cash position of $712.68 million or $9.08 per share.
| Cash & Cash Equivalents | 717.59M |
| Total Debt | 4.90M |
| Net Cash | 712.68M |
| Net Cash Per Share | $9.08 |
| Equity (Book Value) | 714.56M |
| Book Value Per Share | 9.10 |
| Working Capital | 663.61M |
Cash Flow
In the last 12 months, operating cash flow was -$235.57 million and capital expenditures -$6.54 million, giving a free cash flow of -$242.11 million.
| Operating Cash Flow | -235.57M |
| Capital Expenditures | -6.54M |
| Depreciation & Amortization | 3.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -242.11M |
| FCF Per Share | -$3.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | -206,220.25% |
| Pretax Margin | -190,220.89% |
| Profit Margin | n/a |
| EBITDA Margin | -204,070.89% |
| EBIT Margin | -206,220.25% |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -9.18% |
| FCF Yield | -7.39% |
Analyst Forecast
The average price target for CLDX is $58.07, which is 39.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $58.07 |
| Price Target Difference | 39.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 346.77% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |